AstraZeneca Pharma India receives import and market permission from DCGI for Dapagliflozin

AstraZeneca Pharma India Limited has received Import and Market permission in Form CT-20 (Marketing Authorization- Additional Indication) from the Drugs Controller General of India for Dapagliflozin film coated tablet 10mg.

Dapagliflozin film coated tablet 10mg is additional indication in adults for the treatment of heart failure with reduced ejection fraction.

The receipt of this Import and Market permission paves way for launch of Dapagliflozin film coated tablet 10mg in India, subject to the receipt of related statutory approvals and licenses.

Shares of ASTRAZENECA PHARMA INDIA LTD. was last trading in BSE at Rs.3511.95 as compared to the previous close of Rs. 3542.75. The total number of shares traded during the day was 2620 in over 642 trades.

The stock hit an intraday high of Rs. 3568.6 and intraday low of 3488. The net turnover during the day was Rs. 9193662.

Source : Equity Bulls

Keywords